| abstract |
The invention provides piperazine triazine compounds of Formula (I) and They’re pharmaceutically acceptable salts: Formula (I) wherein: R1 is hydrogen, C1-C4alkyl, aryl, substituted aryl, aralkyl, C1-C4alkanoyl, aroyl or C3-C7cycloalkyl; R2 and R3 are respectively aryl, substituted aryl, aralkyl, C1-C4alkaryl or C3-C7cycloalkyl; X is NR7,O,S;R4 and R6 are respectively hydroxyl or C1-C6alkyl; R5 is hydroxyl, C1-C6alkyl,-C(O)R8,-(CH2)mR8,-CH2CH=CHR8,-C(O)OR8,-C(O)OR8 or S(O)2R8, m is 0,1,2 or 3; R7 is hydrogen, hydroxyl or C1-C6alkyl; R8 is hydrogen, hydroxyl, aryl, heteroaryl, heterocyclic radical or C2-C6alkenyl. It is approved that the piperazine triazine compounds of the present invention are epoxy synthase (COX-1 and COX-2) inhibitors with fine curative effect and prevention to clinic inflammation through computer virtuality screening, epoxy synthase(COX-1 and COX-2) combination experiment and pharmacological test. Preparation and pharmaceutical compositions of the compounds are also provided. |